Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib

United European Gastroenterology Journal

Volumn 4, Issue 3, 2016, Pages 363-370

  Iavarone, Massimo ^a   Primignani, Massimo ^a   Vavassori, Sara ^a   Sangiovanni, Angelo ^a   La Mura, Vincenzo ^a   Romeo, Raffaella ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

cirrhosis; Hepatocellular carcinoma; portal hypertension; portal vein thrombosis; upper gastrointestinal endoscopy; varices

Indexed keywords

ALBUMIN; BILIRUBIN; PROPRANOLOL; SORAFENIB;

AGED; ARTICLE; CHRONIC HEPATITIS C; DRUG DOSE REDUCTION; DRUG SAFETY; ESOPHAGUS VARICES BLEEDING; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

EID: 84991764208     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640615615041     Document Type: Article

References (41)

1. J.M.LlovetS.RicciV.Mazzaferro. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med2008; 359: 378–390.
2. A.L.ChengY.K.KangZ.Chen. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol2009; 10: 25–34.
3. D.SemelaA.DasD.Langer. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Gastroenterology2008; 135: 671–679.
4. S.TuguesG.Fernandez-VaroJ.Muñoz-Luque. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology2007; 46: 1919–1926.
5. M.MejiasE.Garcia-PrasC.Tiani. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology2009; 49: 1245–1256.
6. R.CoriatH.GouyaO.Mir. Reversible decrease of portal venous flow in cirrhotic patients: A positive side effect of sorafenib. PLoS One2011; 6: e16978–e16978.
7. M.PinterW.SieghartT.Reiberger. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma—a pilot study. Aliment Pharmacol Ther2012; 35: 83–91.
8. H.HidakaT.NakazawaT.Kaneko. Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: A prospective cohort study. J Gastroenterol2012; 47: 1030–1035.
9. T.KambaD.M.McDonald. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer2007; 96: 1788–1795.
10. R.J.MotzerT.E.HutsonP.Tomczak. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med2007; 356: 115–124.
11. F.EliceJ.JacoubF.R.Rickles. Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol2008; 83: 862–870.
12. P.S.HallK.KancherlaP.S.Sastry. Severe epistaxis with tyrosine kinase inhibitors. Clin Oncol (R Coll Radiol)2008; 20: 318–319.
13. Y.JeF.A.SchutzT.K.Choueiri. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. Lancet Oncol2009; 10: 967–974.
14. G.D.DemetriA.T.van OosteromC.R.Garrett. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet2006; 368: 1329–1338.
15. B.EscudierT.EisenW.M.Stadler. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med2007; 356: 125–134.
16. A.DuffyJ.WilkersonT.F.Greten. Hemorrhagic events in hepatocellular carcinoma patients treated with anti-angiogenic therapies. Hepatology2013; 57: 1068–1077.
17. M.IavaroneG.CabibboF.Piscaglia. Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. Hepatology2011; 54: 2055–2063.
18. J.LlovetC.BrúJ.Bruix. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis1999; 19: 329–338.
19. J.BruixM.Sherman. Management of hepatocellular carcinoma. Hepatology2005; 42: 1208–1236.
20. J.ShiE.C.LaiN.Li. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol2010; 17: 2073–2080.
21. Agenzia Italiana del Farmaco. Registro farmaci oncologici sottoposti a monitoraggio, http://antineoplastici.agenziafarmaco.it/normativa_registro_trast.htm (accessed January 2015)
22. M.M.OkenR.H.CreechD.C.Tormey. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol1982; 5: 649–655.
23. R.N.PughI.M.Murray-LyonJ.L.Dawson. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg1973; 60: 646–649.
24. North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med1988; 319: 983–989.
25. R.De Franchis. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol2005; 43: 167–176.
26. EU summary of product characteristics for Nexavar. Berlin, Germany: Bayer Schering Pharma AG, November 2010
27. Cancer Therapy Evaluation Program, Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS, http://ctep.cancer.gov (31 March 2003, accessed 9 August 2006)
28. R.De Franchis. Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol2010; 53: 762–768.
29. R.De Franchis. Developing consensus in portal hypertension. J Hepatol1996; 25: 390–394.
30. R.De Franchis. Updating consensus in portal hypertension: Report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol2000; 33: 846–852.
31. C.RipollR.GroszmannG.Garcia-Tsao. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology2007; 133: 481–488.
32. A.B.SiegelE.I.CohenA.Ocean. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol2008; 26: 2992–2998.
33. M.B.ThomasJ.S.MorrisR.Chadha. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol2009; 27: 843–850.
34. M.MerliG.NicoliniS.Angeloni. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol2003; 38: 266–272.
35. G.D’AmicoL.PagliaroJ.Bosch. The treatment of portal hypertension: A meta-analytic review. Hepatology1995; 22: 332–354.
36. L.L.GluudA.Krag. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. Cochrane Database Syst Rev2012; 8: CD004544–CD004544.
37. M.ThieleA.KragU.Rohde. Meta-analysis: Banding ligation and medical interventions for the prevention of rebleeding from oesophageal varices. Aliment Pharmacol Ther2012; 35: 1155–1165.
38. C.RipollJ.GenescàI.K.Araujo. Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology2013; 58: 2079–2088.
39. G.CabibboM.EneaM.Attanasio. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology2010; 51: 1274–1283.
40. L.AmitranoM.A.GuardascioneR.Bennato. MELD score and hepatocellular carcinoma identify patients at different risk of short-term mortality among cirrhotics bleeding from esophageal varices. J Hepatol2005; 42: 820–825.
41. K.KadouchiK.HiguchiM.Shiba. What are the risk factors for aggravation of esophageal varices in patients with hepatocellular carcinoma?J Gastroenterol Hepatol2007; 22: 240–246.